NEOGEN2026-08-312026-08-31NEOGEN2026-08-31NEOGEN2026-08-312026-08-31PartiesOfTheAgreementDomain1NEOGEN2026-08-31PartiesOfTheAgreementDomain1NEOGEN2026-08-312026-08-31PartiesOfTheAgreementDomain2NEOGEN2026-08-31PartiesOfTheAgreementDomain2xbrli:purexbrli:sharesNEOGENNeogen Chemicals LimitedNewOthersBusiness Transfer AgreementExecution of agreementRelated Parties of the listed entity,OthersNeogen Ionics Limited (NIL)-a wholly owned subsidiary of Neogen Chemicals Limited (the Company) and Neogen Morita New Materials Limited -a wholly owned subsidiary of NIL and a step down wholly owned subsidiary of the Company.false2026-08-3114:00:00false2026-08-31Board of Directors of Neogen Ionics Limited (“NIL”) – a wholly owned subsidiary of Neogen Chemicals Limited (“the Company”) and the Board of Neogen Morita New Materials Limited (“NML”)- a wholly owned subsidiary of NIL and a step down wholly owned subsidiary of the Company, had at its meeting held today i.e., Monday, August 31, 2026, inter alia considered and approved the Execution of Business Transfer Agreement (“BTA”) between NIL and NML for sale/ transfer of undertaking/ assets as mentioned in detail in the annexure to the BTA by NIL to NML, on a going concern basis, for a lumpsum consideration of Rs. 245 Crore, subject to approval of shareholders of NIL and such regulatory approvals, as may be required and completion of condition precedents as set out in the BTA. Further the necessary approvals were granted by the shareholders of NIL for the said transaction in its meeting held today i.e. August 31, 2026. The Business Transfer Agreement shall be executed in a weeks’ time, between NIL and NML (“BTA”). Likely to be completed on or before March 31, 2027.2026-08-31trueNot Applicable2Neogen Ionics Limited ("NIL")Party entering into the agreement10099000001trueWholly Owned SubsidiaryNeogen Morita New Materials Limited ("NML")Counterparties to the agreement10072000001trueStep Down Wholly owned Subsidiarytruetrue2026-08-31The transfer of the undertaking is part of the Neogen's strategic initiative to consolidate its Electrolyte Salt (LiPF6) businesses under NML.Consideration received from such sale/disposal: The undertaking is proposed to be transferred to NML as a going concern, subject to necessary approvals and customary completion of condition precedents and in accordance with the BTA. The value of such consideration including the relevant assets and after deducting the relevant liabilities, aggregates to a net amount of Rs. 245 Crore. The aforesaid consideration shall be received on or before March 31, 2027, as per the terms and conditions set out under the BTA. Rationale: The transfer of the undertaking is part of the Neogen's strategic initiative to consolidate its Electrolyte Salt (LiPF6) businesses under NML. whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations: The said transaction does not form part of any scheme of arrangement. The said transaction will be undertaken pursuant to the BTA executed between NIL and NML. The said undertaking of NIL does constitute an undertaking in terms of Section 180 of the Companies Act, 2013. Therefore, approvals under Section 180 of the Companies Act, 2013 is obtained. Further as the transaction is between a wholly owned subsidiary (i.e. NIL) and a step-down wholly owned subsidiary (i.e. NML) of the Company (i.e. NCL) the approval under regulation 37A of Listing Regulations is not applicable.falseNot Applicable